共 51 条
Detection of Intact rAAV Particles up to 6 Years After Successful Gene Transfer in the Retina of Dogs and Primates
被引:62
作者:
Stieger, Knut
[2
]
Schroeder, Josef
[3
]
Provost, Nathalie
Mendes-Madeira, Alexandra
Belbellaa, Brahim
Le Meur, Guylene
[4
]
Weber, Michel
[4
]
Deschamps, Jack-Yves
[5
]
Lorenz, Birgit
[2
]
Moullier, Philippe
Rolling, Fabienne
[1
]
机构:
[1] CHU Hotel Dieu, INSERM, U649, Lab Therapie Genique, F-44035 Nantes 01, France
[2] Univ Giessen, Dept Ophthalmol, Giessen, Germany
[3] Univ Regensburg, Inst Pathol, Cent EM Lab, Regensburg, Germany
[4] CHU Hotel Dieu, Serv Ophtalmol, F-44035 Nantes 01, France
[5] Ecole Natl Vet, Serv Urgences, Nantes, France
关键词:
ADENOASSOCIATED VIRUS TYPE-2;
LEBERS CONGENITAL AMAUROSIS;
GROWTH-FACTOR RECEPTOR;
AIRWAY EPITHELIA;
INTRACELLULAR TRAFFICKING;
TRANSDUCTION EFFICIENCY;
PIGMENTED EPITHELIUM;
SUBRETINAL INJECTION;
NUCLEAR TRAFFICKING;
ENDOTHELIAL-CELLS;
D O I:
10.1038/mt.2008.283
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Gene transfer to the retina using recombinant adeno-associated viral (rAAV) vectors has proven to be an effective option for the treatment of retinal degenerative diseases in several animal models and has recently advanced into clinical trials in humans. To date, intracellular trafficking of AAV vectors and subsequent capsid degradation has been studied only in vitro, but the fate of AAV particles in transduced cells following subretinal injection has yet to be elucidated. Using electron microscopy and western blot, we analyzed retinas of one primate and four dogs that had been subretinally injected with AAV2/4, -2/5, or -2/2 serotypes and that displayed efficient gene transfer over several years. We show that intact AAV particles are still present in retinal cells, for up to 6 years after successful gene transfer in these large animals. The persistence of intact vector particles in the target organ, several years postadministration, is totally unexpected and, therefore, represents a new and unanticipated safety issue to consider at a time when gene therapy clinical trials raise new immunological concerns.
引用
收藏
页码:516 / 523
页数:8
相关论文